Orthofix presents a deeply speculative turnaround case: gross margin recovered to 71.0% in 2026Q2, yet quarterly SG&A of roughly $135M has consumed nearly all gross profit, producing operating losses in nine of ten quarters totaling roughly $175M.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.39+4.9% vs -$0.41 | $211M+0.8% vs $209M |
Q2 2026 May 5, 2026 | -$0.52+23.5% vs -$0.68 | $197M+0.2% vs $196M |
Q1 2026 Feb 24, 2026 | -$0.06+70.8% vs -$0.19 | $220M+0.6% vs $219M |
Q4 2025 Nov 4, 2025 | -$0.57-575.0% vs $0.12 | $206M+2.8% vs $200M |
Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on Monday, November 9, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing 833-461-5787 in the U.S., and 585-542-9983 in all other locations, and referencing th.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.
Benchmark OFIX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Orthofix Medical Inc. (OFIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.87 | $318.12M | -5.22 | 2.85% | -7.41% | -14.05% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $7.44 | $1.14B | -13.48 | 24.95% | -10.35% | -547.17% | — | |
| $0.29 | $40.59M | -3.64 | 14.21% | -10.17% | -23.45% | — | |
| $10.78 | $1.77B | -23.17 | 64.69% | -18.64% | — | — | |
| $71.05 | $9.58B | 17.33 | 16.65% | 17.76% | 11.82% | — |
Orthofix Medical Inc. (OFIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Orthofix Medical Inc. (OFIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 2, 2026·SEC
Jun 11, 2026·SEC
Get notified when OFIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Orthofix Medical Inc. (OFIX) stock FAQ — growth, dividends, profitability & financials explained
Orthofix Medical Inc. (OFIX) reported $833.2M in revenue over the trailing twelve months. Revenue was $822.3M in fiscal year 2025. That is 965% more than the $77.2M of fiscal year 1996.
Orthofix Medical Inc. (OFIX) grew revenue by 3.0% over the trailing twelve months, compared with the twelve months before.
No. Orthofix Medical Inc. (OFIX) reported a net loss of $61.7M over the trailing twelve months.
Orthofix Medical Inc. (OFIX) had a return on equity (ROE) of -14.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Orthofix Medical Inc. (OFIX) had negative free cash flow of $27.0M over the trailing twelve months.
